Nautilus Biotechnology, Inc.: insider trades · United States · SEC (Form 4)

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ in the United States under the ticker NAUT. For French-speaking investors, this is best viewed as a high-risk, high-science platform story rather than a mature tools or diagnostics business. The company is developing a single-molecule proteome analysis platform designed to quantify and unlock the complexity of the proteome, with the long-term goal of establishing a new gold standard in proteomics and biomedical research. Nautilus was founded in 2016, is incorporated in Delaware, and became a public company on June 10, 2021 through a combination with a SPAC. Its corporate headquarters are in Seattle, Washington, while its research and development headquarters are in San Carlos, California. ([investors.nautilus.bio](https://investors.nautilus.bio/investor-resources/faqs/?utm_source=openai)) From an industry perspective, Nautilus operates in the emerging proteomics instrumentation and analytical technology space, where competition is shaped by technical sensitivity, workflow robustness, reproducibility, and the ability to generate biologically meaningful insights from highly complex samples. The company is still in a development and validation phase rather than a fully commercial stage. Its future commercial offering is centered on the Voyager platform, alongside proprietary methods such as Iterative Mapping, which Nautilus uses to demonstrate performance and scientific relevance in research applications. Recent work has included assays around Tau proteoforms, highlighting potential relevance to neurodegeneration, oncology, and broader translational research. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai)) In competitive terms, Nautilus is trying to differentiate itself from conventional proteomics approaches by delivering a much deeper, single-molecule view of proteins and proteoforms. That positions the company as a technology platform with potentially meaningful upside if adoption materializes in pharmaceutical R&D, academic research, and biomarker discovery. At the same time, the investment case remains execution-sensitive: scientific promise must still translate into product reliability, customer uptake, and eventual revenue generation. The company has said it is making measurable progress toward commercialization, including an expanded Iterative Mapping Early Access Program and a first customer in an NIH-funded cancer study at Baylor College of Medicine. It also appointed an experienced global sales leader in 2026 to support early customer expansion and future platform adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai)) Geographically, Nautilus remains primarily U.S.-based, with headquarters in Seattle and R&D in the San Francisco Bay Area, but its addressable market is global because proteomics is strategically important to pharmaceutical companies, academic labs, and life-science innovators worldwide. Recent highlights include the release of first-quarter 2026 results, continued progress in sample processing and platform validation, and a deeper push toward commercialization. For investors in Europe, NAUT on NASDAQ should therefore be understood as a United States-listed exposure to a next-generation life-science platform with meaningful long-term optionality, but still at a pre-commercial stage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai))